CDMOs Evolve IT Validation Strategies to Stay Ahead of Market and Regulatory Change

The pace of technological innovation in the pharmaceutical and biotech industries is accelerating rapidly. For contract development and manufacturing organizations (CDMOs), staying competitive now depends on adopting advanced digital technologies, automation, and data-driven systems that improve efficiency, product quality, and speed to market.

As a result, IT validation strategies for both software and hardware must evolve. Modern CDMOs need validation frameworks that ensure regulatory compliance, support faster timelines, and enable continuous improvement across R&D and manufacturing operations.

For additional insights, view the full webinar: Future-Proofing GxP: Strategic Investments and Validation Best Practices for CDMOs Amid Emerging Health Authority Regulations - Xtalks.

The Shift to Risk-Based Validation and CSA in CDMOs

The role of IT within CDMOs has fundamentally changed. No longer limited to infrastructure management, IT teams are now responsible for selecting, implementing, and optimizing digital technologies that directly impact product quality, compliance, and operational efficiency. At Andelyn we are diligently working to harness the power of modern technology to maximize the value of data, drive insights into the data, ensure critical data assets are compliant and secured to provide unmatched data insights for clients through The DIGITAL CDMO® Platform.

With rapid innovation cycles, CDMOs must evaluate and adopt technologies that:

• Automate repetitive tasks
• Improve data integrity and consistency
• Accelerate development timelines
• Enable faster regulatory submissions

From Execution-Focused to Quality-Focused Validation

Historically, validation focused on execution, comprehensive documentation, and testing of every function. Today, regulators such as the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) are promoting a shift toward risk-based validation.

The FDA’s Computer Software Assurance (CSA) guidance reflects this transformation. CSA prioritizes:

·       Critical thinking over excessive documentation

·       Risk assessment of system impact on product quality and patient safety

·       Efficient testing strategies focused on high-risk areas

In parallel, emerging expectations in Europe, reflected in draft updates to EudraLex Annex 11, reinforce this shift while placing greater emphasis on lifecycle control and governance. These include:

·       Ongoing maintenance and periodic review of system requirements throughout the system lifecycle

·       Increased oversight of suppliers and external service providers, including cloud-based systems

·       Strengthened controls for data integrity, including audit trails and traceability

·       Robust management of electronic signatures to ensure authenticity and compliance

·       Enhanced system security measures, including access control and cybersecurity considerations

Together, these developments indicate a broader regulatory shift toward quality-focused validation, where maintaining control, integrity, and reliability of systems over time is as important as initial validation.

This method enables CDMOs to make validation more efficient while staying compliant and prepared for audits.

The Challenge: Skills and Risk Awareness

Transitioning to CSArequires a workforce capable of:

• Understanding business, operational, and technology risks
• Applying risk-based decision-making
• Managing increasingly complex digital ecosystems

Upskilling and reskilling are essential as CDMOs adopt advanced platforms and AI-enabled tools.

AI in IT Validation: Emerging Opportunities

Artificial intelligence is becoming a key enabler in modern validation strategies. CDMOs are exploring AI for:

• Automated log review and anomaly detection
• Data analysis and trend identification
• Process optimization and predictive insights

For example, automating system log reviews, traditionally time-consuming and error-prone, can significantly reduce compliance risk while improving efficiency. To succeed, CDMOs must ensure AI is implemented within a validated, compliant framework that aligns with GxP requirements and data integrity standards.

Continuous Validation and Validation 4.0

Traditional validation models for pharmaceutical equipment were developed in the 1970s, emphasizing exhaustive testing and documentation. However, modern software systems are:

• Rapidly deployed
• Highly interconnected
• Continuously updated

Modern software vendors now use strong Software Development Lifecycle (SDLC) frameworks, automating validation and releases through Continuous Integration and Continuous Delivery (CI/CD) pipelines. In response, modern validation strategies should adopt a similar approach, emphasizing Continuous Validation and Continuous Monitoring (CV/CM) to match these automated workflows.

This makes legacy validation approaches inefficient and unsustainable.

Moving to ContinuousValidation

Under the CSA framework, CDMOs are adopting continuous validation, in which validation becomes an ongoing process embedded in daily operations rather than a one-time event.

Key principles include:

• Integrating validation at system implementation
• Continuously monitoring performance and compliance
• Applying risk-based testing throughout the lifecycle

This approach ensures systems remain validated while adapting to ongoing changes.

Why Continuous Validation Matters

For both equipment andsoftware, most lifecycle effort occurs after installation. In fact:

• Initial installation may represent only ~2% of total lifecycle effort
• Change control, updates, and maintenance drive long-term cost and risk

By optimizing validation during ongoing operations, CDMOs can:

• Reduce compliance risk
• Improve operational efficiency
• Lower long-term validation costs

From Point-in-Time to Process-Centric Validation

Validation 4.0 shifts focus from static validation events to dynamic, process-driven validation. This enables:

• Better integration across multiple systems and platforms
• Real-time data monitoring
• Stronger data integrity and audit readiness

An effective analogy is data sampling. Continuous monitoring provides a clearer, more accurate picture than periodic checks, just as high-frequency data produces a more precise waveform than sparse measurements.

The Role of Automation and Security

Automated testing and monitoring are expected to become standard in IT validation within the next five years. At the same time, regulators and CDMOs are prioritizing:

• Cybersecurity
• Data integrity
• Flexible but controlled validation ecosystems

Successful implementation requires balancing:

• Flexibility for innovation
• Rigidity for compliance

Organizational Alignment and Change Management

Continuous validation is not just a technical shift; it’s an organizational one. Success depends on:

• Cross-functional collaboration
• Clear communication across departments
• Training and user adoption

CDMOs must align business, quality, IT, and regulatory teams to ensure consistent validation practices.

Future Outlook: Building a Proactive Validation Strategy

As digital transformation accelerates, CDMOs must adopt validation strategies that are:

• Risk-based (CSA-driven)
• Continuous (integrated into operations)
• Data-centric (focused on insights and integrity)
• AI-enabled (leveraging automation and analytics)

Organizations that embrace incremental improvements, rather than waiting for perfect solutions, will gain a competitive advantage.

‍

By investing in technology, workforce development, and modern validation frameworks, CDMOs can:

• Maintain compliance with evolving global regulations
• Accelerate time to market
• Deliver higher-quality outcomes for clients and patients

To learn more about Andelyn’s digital CDMO framework, talk to an expert.

‍